1
|
Giardina SF, Werner DS, Pingle M, Bergstrom DE, Arnold LD, Barany F. A Novel, Nonpeptidic, Orally Active Bivalent Inhibitor of Human β-Tryptase. Pharmacology 2018; 102:233-243. [PMID: 30134249 PMCID: PMC6242772 DOI: 10.1159/000492078] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2017] [Accepted: 07/06/2018] [Indexed: 01/15/2023]
Abstract
β-Tryptase is released from mast cells upon degranulation in response to allergic and inflammatory stimuli. Human tryptase is a homotetrameric serine protease with 4 identical active sites directed toward a central pore. These active sites present an optimized scenario for the rational design of bivalent inhibitors, which bridge 2 adjacent active sites. Using (3-[1-acylpiperidin-4-yl]phenyl)methanamine as the pharmacophoric core and a disiloxane linker to span 2 active sites we have successfully produced a novel bivalent tryptase inhibitor, compound 1a, with a comparable profile to previously described inhibitors. Pharmacological properties of compound 1a were studied in a range of in vitro enzymic and cellular screening assays, and in vivo xenograft models. This non-peptide inhibitor of tryptase demonstrated superior activity (IC50 at 100 pmol/L tryptase = 1.82 nmol/L) compared to monomeric modes of inhibition. X-ray crystallography validated the dimeric mechanism of inhibition, and 1a demonstrated good oral bioavailability and efficacy in HMC-1 xenograft models. Furthermore, compound 1a demonstrated extremely slow off rates and high selectivity against-related proteases. This highly potent, orally bioavailable and selective inhibitor of human tryptase will be an invaluable tool in future studies to explore the therapeutic potential of attenuating the activity of this elusive target.
Collapse
Affiliation(s)
- Sarah F Giardina
- Department of Microbiology and Immunology, Joan and Sanford I. Weill Medical College of Cornell University, New York, New York, USA,
| | - Douglas S Werner
- Coferon, Inc., 25 Health Sciences Drive, Stony Brook, New York, USA
- BlinkBio, Inc., The Scripps Research Institute, Jupiter, Florida, USA
| | - Maneesh Pingle
- Department of Microbiology and Immunology, Joan and Sanford I. Weill Medical College of Cornell University, New York, New York, USA
- Coferon, Inc., 25 Health Sciences Drive, Stony Brook, New York, USA
- BlinkBio, Inc., The Scripps Research Institute, Jupiter, Florida, USA
| | - Donald E Bergstrom
- Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana, USA
| | - Lee D Arnold
- Coferon, Inc., 25 Health Sciences Drive, Stony Brook, New York, USA
- Fount Therapeutics, LLC, Wilmington, Delaware, USA
| | - Francis Barany
- Department of Microbiology and Immunology, Joan and Sanford I. Weill Medical College of Cornell University, New York, New York, USA
| |
Collapse
|
2
|
Liu X, Wang J, Zhang H, Zhan M, Chen H, Fang Z, Xu C, Chen H, He S. Induction of Mast Cell Accumulation by Tryptase via a Protease Activated Receptor-2 and ICAM-1 Dependent Mechanism. Mediators Inflamm 2016; 2016:6431574. [PMID: 27378825 PMCID: PMC4917695 DOI: 10.1155/2016/6431574] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2016] [Accepted: 05/10/2016] [Indexed: 02/05/2023] Open
Abstract
Mast cells are primary effector cells of allergy, and recruitment of mast cells in involved tissue is one of the key events in allergic inflammation. Tryptase is the most abundant secretory product of mast cells, but little is known of its influence on mast cell accumulation. Using mouse peritoneal model, cell migration assay, and flow cytometry analysis, we investigated role of tryptase in recruiting mast cells. The results showed that tryptase induced up to 6.7-fold increase in mast cell numbers in mouse peritoneum following injection. Inhibitors of tryptase, an antagonist of PAR-2 FSLLRY-NH2, and pretreatment of mice with anti-ICAM-1, anti-CD11a, and anti-CD18 antibodies dramatically diminished tryptase induced mast cell accumulation. On the other hand, PAR-2 agonist peptides SLIGRL-NH2 and tc-LIGRLO-NH2 provoked mast cell accumulation following injection. These implicate that tryptase induced mast cell accumulation is dependent on its enzymatic activity, activation of PAR-2, and interaction between ICAM-1 and LFA-1. Moreover, induction of trans-endothelium migration of mast cells in vitro indicates that tryptase acts as a chemoattractant. In conclusion, provocation of mast cell accumulation by mast cell tryptase suggests a novel self-amplification mechanism of mast cell accumulation. Mast cell stabilizers as well as PAR-2 antagonist agents may be useful for treatment of allergic reactions.
Collapse
Affiliation(s)
- Xin Liu
- Allergy and Clinical Immunology Research Centre, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning 121001, China
| | - Junling Wang
- Allergy and Clinical Immunology Research Centre, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning 121001, China
| | - Huiyun Zhang
- Allergy and Clinical Immunology Research Centre, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning 121001, China
| | - Mengmeng Zhan
- Allergy and Clinical Immunology Research Centre, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning 121001, China
| | - Hanqiu Chen
- Allergy and Inflammation Research Institute, The Key Immunopathology Laboratory of Guangdong Province, Shantou University Medical College, Shantou 515031, China
| | - Zeman Fang
- Allergy and Inflammation Research Institute, The Key Immunopathology Laboratory of Guangdong Province, Shantou University Medical College, Shantou 515031, China
| | - Chiyan Xu
- Allergy and Inflammation Research Institute, The Key Immunopathology Laboratory of Guangdong Province, Shantou University Medical College, Shantou 515031, China
| | - Huifang Chen
- Allergy and Inflammation Research Institute, The Key Immunopathology Laboratory of Guangdong Province, Shantou University Medical College, Shantou 515031, China
| | - Shaoheng He
- Allergy and Clinical Immunology Research Centre, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning 121001, China
- *Shaoheng He:
| |
Collapse
|
3
|
Nimishakavi S, Raymond WW, Gruenert DC, Caughey GH. Divergent Inhibitor Susceptibility among Airway Lumen-Accessible Tryptic Proteases. PLoS One 2015; 10:e0141169. [PMID: 26485396 PMCID: PMC4612780 DOI: 10.1371/journal.pone.0141169] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2015] [Accepted: 10/04/2015] [Indexed: 12/21/2022] Open
Abstract
Tryptic serine proteases of bronchial epithelium regulate ion flux, barrier integrity, and allergic inflammation. Inhibition of some of these proteases is a strategy to improve mucociliary function in cystic fibrosis and asthmatic inflammation. Several inhibitors have been tested in pre-clinical animal models and humans. We hypothesized that these inhibitors inactivate a variety of airway protease targets, potentially with bystander effects. To establish relative potencies and modes of action, we compared inactivation of human prostasin, matriptase, airway trypsin-like protease (HAT), and β-tryptase by nafamostat, camostat, bis(5-amidino-2-benzimidazolyl)methane (BABIM), aprotinin, and benzamidine. Nafamostat achieved complete, nearly stoichiometric and very slowly reversible inhibition of matriptase and tryptase, but inhibited prostasin less potently and was weakest versus HAT. The IC50 of nafamostat’s leaving group, 6-amidino-2-naphthol, was >104-fold higher than that of nafamostat itself, consistent with suicide rather than product inhibition as mechanisms of prolonged inactivation. Stoichiometric release of 6-amidino-2-naphthol allowed highly sensitive fluorometric estimation of active-site concentration in preparations of matriptase and tryptase. Camostat inactivated all enzymes but was less potent overall and weakest towards matriptase, which, however was strongly inhibited by BABIM. Aprotinin exhibited nearly stoichiometric inhibition of prostasin and matriptase, but was much weaker towards HAT and was completely ineffective versus tryptase. Benzamidine was universally weak. Thus, each inhibitor profile was distinct. Nafamostat, camostat and aprotinin markedly reduced tryptic activity on the apical surface of cystic fibrosis airway epithelial monolayers, suggesting prostasin as the major source of such activity and supporting strategies targeting prostasin for inactivation.
Collapse
Affiliation(s)
- Shilpa Nimishakavi
- Cardiovascular Research Institute, University of California San Francisco, San Francisco, California, United States of America
- Veterans Affairs Medical Center, San Francisco, California, United States of America
| | - Wilfred W. Raymond
- Cardiovascular Research Institute, University of California San Francisco, San Francisco, California, United States of America
- Veterans Affairs Medical Center, San Francisco, California, United States of America
| | - Dieter C. Gruenert
- Cardiovascular Research Institute, University of California San Francisco, San Francisco, California, United States of America
- Department of Otolaryngology-Head and Neck Surgery, University of California San Francisco, San Francisco, California, United States of America
- Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of California San Francisco, San Francisco, California, United States of America
- Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, United States of America
- Institute for Human Genetics, University of California San Francisco, San Francisco, California, United States of America
- Department of Pediatrics, University of Vermont College of Medicine, Burlington, Vermont, United States of America
| | - George H. Caughey
- Cardiovascular Research Institute, University of California San Francisco, San Francisco, California, United States of America
- Veterans Affairs Medical Center, San Francisco, California, United States of America
- Department of Medicine, University of California San Francisco, San Francisco, California, United States of America
- * E-mail:
| |
Collapse
|
4
|
Ammendola M, Leporini C, Marech I, Gadaleta CD, Scognamillo G, Sacco R, Sammarco G, De Sarro G, Russo E, Ranieri G. Targeting mast cells tryptase in tumor microenvironment: a potential antiangiogenetic strategy. Biomed Res Int 2014; 2014:154702. [PMID: 25295247 PMCID: PMC4177740 DOI: 10.1155/2014/154702] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/13/2014] [Revised: 08/14/2014] [Accepted: 08/19/2014] [Indexed: 12/13/2022]
Abstract
Angiogenesis is a complex process finely regulated by the balance between angiogenesis stimulators and inhibitors. As a result of proangiogenic factors overexpression, it plays a crucial role in cancer development. Although initially mast cells (MCs) role has been defined in hypersensitivity reactions and in immunity, it has been discovered that MCs have a crucial interplay on the regulatory function between inflammatory and tumor cells through the release of classical proangiogenic factors (e.g., vascular endothelial growth factor) and nonclassical proangiogenic mediators granule-associated (mainly tryptase). In fact, in several animal and human malignancies, MCs density is highly correlated with tumor angiogenesis. In particular, tryptase, an agonist of the proteinase-activated receptor-2 (PAR-2), represents one of the most powerful angiogenic mediators released by human MCs after c-Kit receptor activation. This protease, acting on PAR-2 by its proteolytic activity, has angiogenic activity stimulating both human vascular endothelial and tumor cell proliferation in paracrine manner, helping tumor cell invasion and metastasis. Based on literature data it is shown that tryptase may represent a promising target in cancer treatment due to its proangiogenic activity. Here we focused on molecular mechanisms of three tryptase inhibitors (gabexate mesylate, nafamostat mesylate, and tranilast) in order to consider their prospective role in cancer therapy.
Collapse
Affiliation(s)
- Michele Ammendola
- Department of Medical and Surgery Sciences, Clinical Surgery Unit, University “Magna Graecia” Medical School, Viale Europa, Germaneto, 88100 Catanzaro, Italy
| | - Christian Leporini
- Department of Health Science, Clinical Pharmacology and Pharmacovigilance Unit and Pharmacovigilance's Centre Calabria Region, University of Catanzaro “Magna Graecia” Medical School, Viale Europa, Germaneto, 88100 Catanzaro, Italy
| | - Ilaria Marech
- Diagnostic and Interventional Radiology Unit with Integrated Section of Translational Medical Oncology, Istituto Tumori “Giovanni Paolo II,” Viale Orazio Flacco 65, 70124 Bari, Italy
| | - Cosmo Damiano Gadaleta
- Diagnostic and Interventional Radiology Unit with Integrated Section of Translational Medical Oncology, Istituto Tumori “Giovanni Paolo II,” Viale Orazio Flacco 65, 70124 Bari, Italy
| | - Giovanni Scognamillo
- Radiotherapy Unit, Istituto Tumori “Giovanni Paolo II,” Viale Orazio Flacco 65, 70124 Bari, Italy
| | - Rosario Sacco
- Department of Medical and Surgery Sciences, Clinical Surgery Unit, University “Magna Graecia” Medical School, Viale Europa, Germaneto, 88100 Catanzaro, Italy
| | - Giuseppe Sammarco
- Department of Medical and Surgery Sciences, Clinical Surgery Unit, University “Magna Graecia” Medical School, Viale Europa, Germaneto, 88100 Catanzaro, Italy
| | - Giovambattista De Sarro
- Department of Health Science, Clinical Pharmacology and Pharmacovigilance Unit and Pharmacovigilance's Centre Calabria Region, University of Catanzaro “Magna Graecia” Medical School, Viale Europa, Germaneto, 88100 Catanzaro, Italy
| | - Emilio Russo
- Department of Health Science, Clinical Pharmacology and Pharmacovigilance Unit and Pharmacovigilance's Centre Calabria Region, University of Catanzaro “Magna Graecia” Medical School, Viale Europa, Germaneto, 88100 Catanzaro, Italy
| | - Girolamo Ranieri
- Diagnostic and Interventional Radiology Unit with Integrated Section of Translational Medical Oncology, Istituto Tumori “Giovanni Paolo II,” Viale Orazio Flacco 65, 70124 Bari, Italy
| |
Collapse
|
5
|
Valdés JJ, Schwarz A, Cabeza de Vaca I, Calvo E, Pedra JHF, Guallar V, Kotsyfakis M. Tryptogalinin is a tick Kunitz serine protease inhibitor with a unique intrinsic disorder. PLoS One 2013; 8:e62562. [PMID: 23658744 PMCID: PMC3643938 DOI: 10.1371/journal.pone.0062562] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2013] [Accepted: 03/22/2013] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND A salivary proteome-transcriptome project on the hard tick Ixodes scapularis revealed that Kunitz peptides are the most abundant salivary proteins. Ticks use Kunitz peptides (among other salivary proteins) to combat host defense mechanisms and to obtain a blood meal. Most of these Kunitz peptides, however, remain functionally uncharacterized, thus limiting our knowledge about their biochemical interactions. RESULTS We discovered an unusual cysteine motif in a Kunitz peptide. This peptide inhibits several serine proteases with high affinity and was named tryptogalinin due to its high affinity for β-tryptase. Compared with other functionally described peptides from the Acari subclass, we showed that tryptogalinin is phylogenetically related to a Kunitz peptide from Rhipicephalus appendiculatus, also reported to have a high affinity for β-tryptase. Using homology-based modeling (and other protein prediction programs) we were able to model and explain the multifaceted function of tryptogalinin. The N-terminus of the modeled tryptogalinin is detached from the rest of the peptide and exhibits intrinsic disorder allowing an increased flexibility for its high affinity with its inhibiting partners (i.e., serine proteases). CONCLUSIONS By incorporating experimental and computational methods our data not only describes the function of a Kunitz peptide from Ixodes scapularis, but also allows us to hypothesize about the molecular basis of this function at the atomic level.
Collapse
Affiliation(s)
- James J Valdés
- Institute of Parasitology, Biology Centre of the Academy of Sciences of the Czech Republic, České Budějovice, Czech Republic.
| | | | | | | | | | | | | |
Collapse
|
6
|
Zhang H, Yang H, Ma W, Zhang Z, He S. Modulation of PAR expression and tryptic enzyme induced IL-4 production in mast cells by IL-29. Cytokine 2013; 61:469-77. [PMID: 23218741 DOI: 10.1016/j.cyto.2012.10.032] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2012] [Revised: 09/17/2012] [Accepted: 10/31/2012] [Indexed: 12/25/2022]
Abstract
Interleukin (IL)-29 is a relatively newly discovered cytokine, which has been shown to be actively involved in the pathogenesis of allergic inflammation. However, little is known of the effects of IL-29 on protease activated receptor (PAR) expression and potential mechanisms of cytokine production in mast cells. In the present study, we examined potential influence of IL-29 on PAR expression and cytokine production in P815 and bone marrow derived mast cells (BMMCs) by using flow cytometry analysis, quantitative real time PCR, and ELISA techniques. The results showed that IL-29 downregulated the expression of PAR-1 by up to 56.2%, but had little influence on the expression of PAR-2, PAR-3 and PAR-4. IL-29 also induced downregulation of expression of PAR-1 mRNA. However, when mast cells were pre-incubated with IL-29, thrombin-, trypsin- and tryptase-induced expression of PAR-2, PAR-3 and PAR-4 was upregulated, respectively. IL-29 provoked approximately up to 1.9-fold increase in IL-4 release when mast cells was challenged with IL-29. Administration of IL-29 blocking antibody, AG490 or LY294002 abolished IL-29-induced IL-4 release from P815 cells. It was found that IL-29 diminished trypsin- and tryptase-induced IL-4 release from P815 cells following 16 h incubation. In conclusion, IL-29 can regulate expression of PARs and tryptase- and trypsin-induced IL-4 production in mast cells, through which participates in the mast cell related inflammation.
Collapse
Affiliation(s)
- Huiyun Zhang
- Department of Pathophysiology, Hainan Medical College, Haikou, Hainan 571101, China
| | | | | | | | | |
Collapse
|
7
|
Abstract
Tyrosinase, trypsin, and tryptase are known to play important roles in melanin production of human skin. This paper describes the study of the inhibitory effect of Balanophora fungosa on melanin. The 50% EtOH extract obtained from B. fungosa indicated an inhibitory effect on mushroom tyrosinase activity with an IC(50) value of 15 μg/mL. Bioassay-guided fractionation of the active extract resulted in the isolation of four known compounds. Their structures were identified as 1-O-(E)-caffeoyl-3-O-galloyl-4,6-(S)-HHDP-β-d-glucopyranose (1), 1-O-(E)-caffeoyl-3,4,6-tri-O-galloyl-β-d-glucopyranose (2), caffeoyl-β-d-glucopyranose (3), and abietin (4) on the basis of spectroscopic analyses and comparison of their spectral data with those in the literature. Compounds 1 and 2 prevented pigmentation of melanin in a three-dimensional cultured human skin model. Furthermore, compounds 1 and 2 indicated inhibitory activities against trypsin and tryptase.
Collapse
Affiliation(s)
- Takayuki Ogi
- Okinawa Industrial Technology Center, 12-2 Suzaki, Uruma, Okinawa 901-2213, Japan.
| | | | | |
Collapse
|
8
|
Tatler AL, Porte J, Knox A, Jenkins G, Pang L. Tryptase activates TGFbeta in human airway smooth muscle cells via direct proteolysis. Biochem Biophys Res Commun 2008; 370:239-42. [PMID: 18359288 DOI: 10.1016/j.bbrc.2008.03.064] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2008] [Accepted: 03/14/2008] [Indexed: 11/16/2022]
Abstract
Transforming growth factor beta (TGFbeta) is a key remodelling factor in asthma. It is produced as a latent complex and the main limiting step in TGFbeta bioavailability is its activation. Mast cell tryptase has been shown to stimulate the release of functionally active TGFbeta from human airway smooth muscle (ASM) cells [P. Berger, P.O. Girodet, H. Begueret, O. Ousova, D.W. Perng, R. Marthan, A.F. Walls, J.M. Tunon de Lara, Tryptase-stimulated human airway smooth muscle cells induce cytokine synthesis and mast cell chemotaxis, FASEB J. 17 (2003) 2139-2141]. The aim of this study was to determine if tryptase could cause TGFbeta activation as well as expression in ASM cells via its receptor, proteinase-activated receptor 2 (PAR2). Tryptase caused TGFbeta activation without affecting levels of total TGFbeta. This effect was inhibited by the selective tryptase inhibitor FUT175 and leupeptin but not mimicked by the PAR2 activating peptide SLIGKV-NH(2). Furthermore, the ASM cells used in the study did not express PAR2. The results indicate that tryptase activates TGFbeta via a PAR2-independent proteolytic mechanism in human ASM cells and may help understanding the role of tryptase in asthma.
Collapse
Affiliation(s)
- Amanda L Tatler
- Centre for Respiratory Research, Clinical Sciences Building, City Hospital, University of Nottingham, Hucknall Road, Nottingham NG5 1PB, UK.
| | | | | | | | | |
Collapse
|
9
|
Costanzo MJ, Yabut SC, Zhang HC, White KB, de Garavilla L, Wang Y, Minor LK, Tounge BA, Barnakov AN, Lewandowski F, Milligan C, Spurlino JC, Abraham WM, Boswell-Smith V, Page CP, Maryanoff BE. Potent, nonpeptide inhibitors of human mast cell tryptase. Synthesis and biological evaluation of novel spirocyclic piperidine amide derivatives. Bioorg Med Chem Lett 2008; 18:2114-21. [PMID: 18272363 DOI: 10.1016/j.bmcl.2008.01.093] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2007] [Revised: 01/21/2008] [Accepted: 01/23/2008] [Indexed: 11/18/2022]
Abstract
We have explored a series of spirocyclic piperidine amide derivatives (5) as tryptase inhibitors. Thus, 4 (JNJ-27390467) was identified as a potent, selective tryptase inhibitor with oral efficacy in two animal models of airway inflammation (sheep and guinea pig asthma models). An X-ray co-crystal structure of 4 x tryptase revealed a hydrophobic pocket in the enzyme's active site, which is induced by the phenylethynyl group and is comprised of amino acid residues from two different monomers of the tetrameric protein.
Collapse
Affiliation(s)
- Michael J Costanzo
- Research and Early Development, Johnson & Johnson Pharmaceutical Research & Development, Welsh & McKean Roads, Spring House, PA 19477-0776, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Stevens RL, Adachi R. Protease-proteoglycan complexes of mouse and human mast cells and importance of their beta-tryptase-heparin complexes in inflammation and innate immunity. Immunol Rev 2007; 217:155-67. [PMID: 17498058 DOI: 10.1111/j.1600-065x.2007.00525.x] [Citation(s) in RCA: 112] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Approximately 50% of the weight of a mature mast cell (MC) consists of varied neutral proteases stored in the cell's secretory granules ionically bound to serglycin proteoglycans that contain heparin and/or chondroitin sulfate E/diB chains. Mouse MCs express the exopeptidase carboxypeptidase A3 and at least 15 serine proteases [designated as mouse MC protease (mMCP) 1-11, transmembrane tryptase/tryptase gamma/protease serine member S (Prss) 31, cathepsin G, granzyme B, and neuropsin/Prss19]. mMCP-6, mMCP-7, mMCP-11/Prss34, and Prss31 are the four members of the chromosome 17A3.3 family of tryptases that are preferentially expressed in MCs. One of the challenges ahead is to understand why MCs express so many different protease-proteoglycan macromolecular complexes. MC-like cells that contain tryptase-heparin complexes in their secretory granules have been identified in the Ciona intestinalis and Styela plicata urochordates that appeared approximately 500 million years ago. Because sea squirts lack B cells and T cells, it is likely that MCs and their tryptase-proteoglycan granule mediators initially appeared in lower organisms as part of their innate immune system. The conservation of MCs throughout evolution suggests that some of these protease-proteoglycan complexes are essential to our survival. In support of this conclusion, no human has been identified that lacks MCs. Moreover, transgenic mice lacking the beta-tryptase mMCP-6 are unable to combat a Klebsiella pneumoniae infection effectively. Here we summarize the nature and function of some of the tryptase-serglycin proteoglycan complexes found in mouse and human MCs.
Collapse
Affiliation(s)
- Richard L Stevens
- Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA.
| | | |
Collapse
|
11
|
Schumacher WA, Seiler SE, Steinbacher TE, Stewart AB, Bostwick JS, Hartl KS, Liu EC, Ogletree ML. Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats. Eur J Pharmacol 2007; 570:167-74. [PMID: 17597608 DOI: 10.1016/j.ejphar.2007.05.043] [Citation(s) in RCA: 69] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2007] [Revised: 05/18/2007] [Accepted: 05/22/2007] [Indexed: 11/30/2022]
Abstract
The effect of inhibiting activated blood coagulation factor XIa was determined in rat models of thrombosis and hemostasis. BMS-262084 is an irreversible and selective small molecule inhibitor of factor XIa with an IC(50) of 2.8 nM against human factor XIa. BMS-262084 doubled the activated thromboplastin time in human and rat plasma at 0.14 and 2.2 microM, respectively. Consistent with factor XIa inhibition, the prothrombin time was unaffected at up to 100 microM. BMS-262084 administered as an intravenous loading plus sustaining infusion was effective against FeCl(2)-induced thrombosis in both the vena cava and carotid artery. Maximum thrombus weight reductions of 97 and 73%, respectively (P<0.05), were achieved at a pretreatment dose of 12 mg/kg+12 mg/kg/h which increased the ex vivo activated thromboplastin time to 3.0 times control. This dose level also arrested growth of venous and arterial thrombi when administered after partial thrombus formation. BMS-262084 was most potent in FeCl(2)-induced venous thrombosis, decreasing thrombus weight 38% (P<0.05) at a threshold dose of 0.2 mg/kg+0.2 mg/kg/h. In contrast, doses of up to 24 mg/kg+24 mg/kg/h had no effect on either tissue factor-induced venous thrombosis or the ex vivo prothrombin time. Doses of up to 24 mg/kg+24 mg/kg/h also did not significantly prolong bleeding time provoked by either puncture of small mesenteric blood vessels, template incision of the renal cortex, or cuticle incision. These results demonstrate that pharmacologic inhibition of factor XIa achieves antithrombotic efficacy with minimal effects on provoked bleeding.
Collapse
Affiliation(s)
- William A Schumacher
- Discovery Biology, Bristol-Myers Squibb Company, Pennington, New Jersey 08534, USA.
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Hamuro T, Kido H, Asada Y, Hatakeyama K, Okumura Y, Kunori Y, Kamimura T, Iwanaga S, Kamei S. Tissue factor pathway inhibitor is highly susceptible to chymase-mediated proteolysis. FEBS J 2007; 274:3065-77. [PMID: 17509077 DOI: 10.1111/j.1742-4658.2007.05833.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Tissue factor pathway inhibitor (TFPI) is a multivalent Kunitz-type protease inhibitor that primarily inhibits the extrinsic pathway of blood coagulation. It is synthesized by various cells and its expression level increases in inflammatory environments. Mast cells and neutrophils accumulate at sites of inflammation and vascular disease where they release proteinases as well as chemical mediators of these conditions. In this study, the interactions between TFPI and serine proteinases secreted from human mast cells and neutrophils were examined. TFPI inactivated human lung tryptase, and its inhibitory activity was stronger than that of antithrombin. In contrast, mast cell chymase rapidly cleaved TFPI even at an enzyme to substrate molar ratio of 1:500, resulting in markedly decreased TFPI anticoagulant and anti-(factor Xa) activities. N-terminal amino-acid sequencing and MS analyses of the proteolytic fragments revealed that chymase preferentially cleaved TFPI at Tyr159-Gly160, Phe181-Glu182, Leu89-Gln90, and Tyr268-Glu269, in that order, resulting in the separation of the three individual Kunitz domains. Neutrophil-derived proteinase 3 also cleaved TFPI, but the reaction was much slower than the chymase reaction. In contrast, alpha-chymotrypsin, which shows similar substrate specificities to those of chymase, resulted in a markedly lower level of TFPI degradation. These data indicate that TFPI is a novel and highly susceptible substrate of chymase. We propose that chymase-mediated proteolysis of TFPI may induce a thrombosis-prone state at inflammatory sites.
Collapse
Affiliation(s)
- Tsutomu Hamuro
- Therapeutic Protein Products Research Department, The Chemo-Sero-Therapeutic Research Institute, Kaketsuken, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Abstract
Tryptases comprise a group of trypsin-like serine proteases that are highly and selectively expressed in mast cells and to a lesser extent in basophils. Among them interest has been focused on tryptase beta, primarily because it was the first tryptase identified and because it is the predominant protease and protein component of mast cells. Subsequent studies have provided convincing evidence that tryptase beta is not only a clinically useful marker of mast cells and their activation but that it contributes to the pathogenesis of allergic inflammatory disorders, most notably asthma. The pathogenetic relevance together with the apparent lack of overt physiological functions has caused considerable interest in beta-tryptase as a potential therapeutic target. Meanwhile diverse tryptase inhibitors have been synthesized whose design in part was fostered by the structural analysis of the enzymatically active beta tryptase tetramer. Various compounds have been studied both in animal models and in man, providing proof of principle that tryptase inhibitors have therapeutic potential in asthma. Here we review the rationale to develop tryptase inhibitors and the approaches pursued, and also try to pinpoint some of the problems that hamper the development of clinically applicable drugs.
Collapse
Affiliation(s)
- C P Sommerhoff
- Abteilung Klinische Chemie und Klinische Biochemie, Klinikum der Ludwig-Maximilians-Universität, München, Germany.
| | | |
Collapse
|
14
|
Paesen GC, Siebold C, Harlos K, Peacey MF, Nuttall PA, Stuart DI. A tick protein with a modified Kunitz fold inhibits human tryptase. J Mol Biol 2007; 368:1172-86. [PMID: 17391695 DOI: 10.1016/j.jmb.2007.03.011] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2006] [Revised: 03/03/2007] [Accepted: 03/07/2007] [Indexed: 11/24/2022]
Abstract
TdPI, a tick salivary gland product related to Kunitz/BPTI proteins is a potent inhibitor of human beta-tryptase. Kinetic assays suggest that three of the four catalytic sites of tryptase are blocked by TdPI, and that the inhibition of one of these involves a peptide flanking the Kunitz head. In the course of the inhibition, tryptase cleaves TdPI at several positions. Crystal structures of the TdPI head, on its own and in complex with trypsin, reveal features that are not found in classical Kunitz/BPTI proteins and suggest the mode of interaction with tryptase. The loop of TdPI connecting the beta-sheet with the C-terminal alpha-helix is shortened, the disulphide-bridge pattern altered and N and C termini separated to produce a highly pointed molecule capable of penetrating the cramped active sites of tryptase. TdPI accumulates in the cytosolic granules of mast cells, presumably suppressing inflammation in the host animal's skin by tryptase inhibition.
Collapse
|
15
|
Cenac N, Andrews CN, Holzhausen M, Chapman K, Cottrell G, Andrade-Gordon P, Steinhoff M, Barbara G, Beck P, Bunnett NW, Sharkey KA, Ferraz JGP, Shaffer E, Vergnolle N. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 2007; 117:636-47. [PMID: 17304351 PMCID: PMC1794118 DOI: 10.1172/jci29255] [Citation(s) in RCA: 431] [Impact Index Per Article: 25.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2006] [Accepted: 12/05/2006] [Indexed: 12/12/2022] Open
Abstract
Mediators involved in the generation of symptoms in patients with irritable bowel syndrome (IBS) are poorly understood. Here we show that colonic biopsy samples from IBS patients release increased levels of proteolytic activity (arginine cleavage) compared to asymptomatic controls. This was dependent on the activation of NF-kappaB. In addition, increased proteolytic activity was measured in vivo, in colonic washes from IBS compared with control patients. Trypsin and tryptase expression and release were increased in colonic biopsies from IBS patients compared with control subjects. Biopsies from IBS patients (but not controls) released mediators that sensitized murine sensory neurons in culture. Sensitization was prevented by a serine protease inhibitor and was absent in neurons lacking functional protease-activated receptor-2 (PAR2). Supernatants from colonic biopsies of IBS patients, but not controls, also caused somatic and visceral hyperalgesia and allodynia in mice, when administered into the colon. These pronociceptive effects were inhibited by serine protease inhibitors and a PAR2 antagonist and were absent in PAR2-deficient mice. Our study establishes that proteases are released in IBS and that they can directly stimulate sensory neurons and generate hypersensitivity symptoms through the activation of PAR2.
Collapse
Affiliation(s)
- Nicolas Cenac
- Department of Pharmacology and Therapeutics and
Department of Medicine, Division of Gastroenterology, University of Calgary, Calgary, Alberta, Canada.
Departments of Surgery and Physiology, UCSF, San Francisco, California, USA.
R.W. Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania, USA.
Department of Dermatology and Interdisciplinary Center for Clinical Research (IZKF) Münster, University of Münster, Münster, Germany.
Departments of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy.
Department of Physiology and Biophysics, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Christopher N. Andrews
- Department of Pharmacology and Therapeutics and
Department of Medicine, Division of Gastroenterology, University of Calgary, Calgary, Alberta, Canada.
Departments of Surgery and Physiology, UCSF, San Francisco, California, USA.
R.W. Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania, USA.
Department of Dermatology and Interdisciplinary Center for Clinical Research (IZKF) Münster, University of Münster, Münster, Germany.
Departments of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy.
Department of Physiology and Biophysics, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Marinella Holzhausen
- Department of Pharmacology and Therapeutics and
Department of Medicine, Division of Gastroenterology, University of Calgary, Calgary, Alberta, Canada.
Departments of Surgery and Physiology, UCSF, San Francisco, California, USA.
R.W. Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania, USA.
Department of Dermatology and Interdisciplinary Center for Clinical Research (IZKF) Münster, University of Münster, Münster, Germany.
Departments of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy.
Department of Physiology and Biophysics, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Kevin Chapman
- Department of Pharmacology and Therapeutics and
Department of Medicine, Division of Gastroenterology, University of Calgary, Calgary, Alberta, Canada.
Departments of Surgery and Physiology, UCSF, San Francisco, California, USA.
R.W. Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania, USA.
Department of Dermatology and Interdisciplinary Center for Clinical Research (IZKF) Münster, University of Münster, Münster, Germany.
Departments of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy.
Department of Physiology and Biophysics, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Graeme Cottrell
- Department of Pharmacology and Therapeutics and
Department of Medicine, Division of Gastroenterology, University of Calgary, Calgary, Alberta, Canada.
Departments of Surgery and Physiology, UCSF, San Francisco, California, USA.
R.W. Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania, USA.
Department of Dermatology and Interdisciplinary Center for Clinical Research (IZKF) Münster, University of Münster, Münster, Germany.
Departments of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy.
Department of Physiology and Biophysics, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Patricia Andrade-Gordon
- Department of Pharmacology and Therapeutics and
Department of Medicine, Division of Gastroenterology, University of Calgary, Calgary, Alberta, Canada.
Departments of Surgery and Physiology, UCSF, San Francisco, California, USA.
R.W. Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania, USA.
Department of Dermatology and Interdisciplinary Center for Clinical Research (IZKF) Münster, University of Münster, Münster, Germany.
Departments of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy.
Department of Physiology and Biophysics, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Martin Steinhoff
- Department of Pharmacology and Therapeutics and
Department of Medicine, Division of Gastroenterology, University of Calgary, Calgary, Alberta, Canada.
Departments of Surgery and Physiology, UCSF, San Francisco, California, USA.
R.W. Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania, USA.
Department of Dermatology and Interdisciplinary Center for Clinical Research (IZKF) Münster, University of Münster, Münster, Germany.
Departments of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy.
Department of Physiology and Biophysics, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Giovanni Barbara
- Department of Pharmacology and Therapeutics and
Department of Medicine, Division of Gastroenterology, University of Calgary, Calgary, Alberta, Canada.
Departments of Surgery and Physiology, UCSF, San Francisco, California, USA.
R.W. Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania, USA.
Department of Dermatology and Interdisciplinary Center for Clinical Research (IZKF) Münster, University of Münster, Münster, Germany.
Departments of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy.
Department of Physiology and Biophysics, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Paul Beck
- Department of Pharmacology and Therapeutics and
Department of Medicine, Division of Gastroenterology, University of Calgary, Calgary, Alberta, Canada.
Departments of Surgery and Physiology, UCSF, San Francisco, California, USA.
R.W. Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania, USA.
Department of Dermatology and Interdisciplinary Center for Clinical Research (IZKF) Münster, University of Münster, Münster, Germany.
Departments of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy.
Department of Physiology and Biophysics, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Nigel W. Bunnett
- Department of Pharmacology and Therapeutics and
Department of Medicine, Division of Gastroenterology, University of Calgary, Calgary, Alberta, Canada.
Departments of Surgery and Physiology, UCSF, San Francisco, California, USA.
R.W. Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania, USA.
Department of Dermatology and Interdisciplinary Center for Clinical Research (IZKF) Münster, University of Münster, Münster, Germany.
Departments of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy.
Department of Physiology and Biophysics, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Keith A. Sharkey
- Department of Pharmacology and Therapeutics and
Department of Medicine, Division of Gastroenterology, University of Calgary, Calgary, Alberta, Canada.
Departments of Surgery and Physiology, UCSF, San Francisco, California, USA.
R.W. Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania, USA.
Department of Dermatology and Interdisciplinary Center for Clinical Research (IZKF) Münster, University of Münster, Münster, Germany.
Departments of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy.
Department of Physiology and Biophysics, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Jose Geraldo P. Ferraz
- Department of Pharmacology and Therapeutics and
Department of Medicine, Division of Gastroenterology, University of Calgary, Calgary, Alberta, Canada.
Departments of Surgery and Physiology, UCSF, San Francisco, California, USA.
R.W. Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania, USA.
Department of Dermatology and Interdisciplinary Center for Clinical Research (IZKF) Münster, University of Münster, Münster, Germany.
Departments of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy.
Department of Physiology and Biophysics, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Eldon Shaffer
- Department of Pharmacology and Therapeutics and
Department of Medicine, Division of Gastroenterology, University of Calgary, Calgary, Alberta, Canada.
Departments of Surgery and Physiology, UCSF, San Francisco, California, USA.
R.W. Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania, USA.
Department of Dermatology and Interdisciplinary Center for Clinical Research (IZKF) Münster, University of Münster, Münster, Germany.
Departments of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy.
Department of Physiology and Biophysics, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Nathalie Vergnolle
- Department of Pharmacology and Therapeutics and
Department of Medicine, Division of Gastroenterology, University of Calgary, Calgary, Alberta, Canada.
Departments of Surgery and Physiology, UCSF, San Francisco, California, USA.
R.W. Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania, USA.
Department of Dermatology and Interdisciplinary Center for Clinical Research (IZKF) Münster, University of Münster, Münster, Germany.
Departments of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy.
Department of Physiology and Biophysics, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
| |
Collapse
|
16
|
Peterson CGB, Hansson T, Skott A, Bengtsson U, Ahlstedt S, Magnussons J. Detection of local mast-cell activity in patients with food hypersensitivity. J Investig Allergol Clin Immunol 2007; 17:314-320. [PMID: 17982924] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2023] Open
Abstract
BACKGROUND Mast cells play a central role in many inflammatory diseases and assessment of their activation may be of use to provide objective confirmation of the outcome of food challenge in the diagnosis of food hypersensitivity. However, to date, assessment of mast-cell activation using serum markers has been unsuccessful. OBJECTIVE The aim of this study was to explore whether locally released tryptase could be detected in stool samples from patients with food hypersensitivity. METHODS Nine patients (median age, 55 years; range, 26 - 68 years) with food hypersensitivity confirmed by double-blind placebo-controlled food challenge were included in the study. Tryptase concentration was assessed in stool samples collected before and after an open food challenge at home and symptoms were recorded throughout the study. Tryptase concentration was also assessed in stool samples from 16 apparently healthy individuals (median age, 44 years; range, 27 - 72 years). RESULTS Measurement of fecal tryptase levels in 16 healthy control subjects revealed an upper limit of the normal range (mean + 2 SD of log transformed data) of 10 ng/g. Fecal tryptase levels exceeded 10 ng/g in 7 out of 9 patients in one or more samples obtained during the study. The tryptase levels varied between patients in response to the food challenge and the individual mean levels of tryptase correlated with the corresponding levels of the inflammatory marker eosinophil protein X (rho = 0.7500, P = .02). CONCLUSION Measurement of tryptase levels in stool samples is feasible using the method described here. Our results revealed elevated concentrations of fecal tryptase in patients with food hypersensitivity. However, several factors, including food exposure, may account for the increase in fecal tryptase and further studies are necessary to elucidate the role of mast cells in food hypersensitivity.
Collapse
Affiliation(s)
- C G B Peterson
- Department of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden.
| | | | | | | | | | | |
Collapse
|
17
|
Isozaki Y, Yoshida N, Kuroda M, Handa O, Takagi T, Kokura S, Ichikawa H, Naito Y, Okanoue T, Yoshikawa T. Anti-tryptase treatment using nafamostat mesilate has a therapeutic effect on experimental colitis. Scand J Gastroenterol 2006; 41:944-53. [PMID: 16803693 DOI: 10.1080/00365520500529470] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
OBJECTIVE Mast cell tryptase has been proposed to be involved in the pathogenesis of human inflammatory bowel disease (IBD). Recently, it was reported that a low dose of nafamostat mesilate (NM), a serine protease inhibitor that is widely used to treat disseminated intravascular coagulation (DIC) and acute pancreatitis, can selectively inhibit human tryptase activity. The aim of this study was to investigate the anti-inflammatory effects of NM on experimental colitis in rats. MATERIAL AND METHODS Colitis was induced in male Wistar rats using an enema of trinitrobenzene sulfonic acid (TNBS) dissolved in 50% ethanol. NM or 5-aminosalicylic acid (5-ASA), foundation therapy for mild-to-moderate IBD, was administered via the anus once a day on each of the 6 days after administration of TNBS. Colonic inflammation was assessed 1 week after TNBS administration. RESULTS Intracolonic administration of TNBS resulted in the infiltration of numerous tryptase-positive cells in the colonic mucosa. The colonic mucosal injury induced by TNBS was significantly decreased by treatment with NM or 5-ASA. The increases in thiobarbituric acid-reactive substances (TBA-RS), myeloperoxidase (MPO) activity, tumor necrosis factor (TNF)-alpha and cytokine-induced neutrophil chemoattractants-1 (CINC-1) in the colonic mucosa were inhibited in the NM group and the 5-ASA group, without significant differences between them. CONCLUSIONS These results indicate that a low dose of NM can inhibit the colonic mucosal inflammation induced by TNBS in rats, which suggests that anti-tryptase therapy using low doses of NM has excellent potential to become a new therapeutic strategy for IBD.
Collapse
Affiliation(s)
- Yutaka Isozaki
- Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|